Data Characteristics in Bioequivalence
Bioequivalence pharmacovigilance data originates from clinical trial reports, real-world evidence (RWE) data, adverse event (AE) reporting systems, and literature databases. Data update frequencies vary. Clinical trial reports are typically released after a study concludes. RWE data collection can be ongoing. Adverse event reporting systems update in real-time or near real-time. Document structures are diverse, including structured Case Report Forms (CRFs), semi-structured medical narratives, and unstructured Investigator's Brochures (IBs) and regulatory submission documents. Key fields include drug batch information, subject demographics, dosing regimens, bioanalytical results (e.g., plasma concentration-time curves), adverse event types and severity, causality assessments, and management actions. Units involve dosage (mg), concentration (ng/mL), time (h), and biomarker values. Data often includes confidence intervals and statistical metrics.
Constraints on Multi-turn Conversations and Prompts
The diversity and complexity of bioequivalence data impose specific requirements on multi-turn conversation and prompt design. First, disparate data sources mean a single conversation may need to aggregate information from multiple sources. This requires prompts to guide the model in cross-document information retrieval. Second, varied document structures mean unstructured text requires stronger semantic understanding. Prompt design must focus on extracting and summarizing key information. For example, identifying specific adverse event descriptions and related drug batches from medical narratives. Third, inconsistent data update frequencies mean the validity of historical conversation records can be affected by data timeliness. Prompts need to guide users to confirm the latest information status. Finally, the accuracy of specialized terminology and measurement units is critical. Prompts should restrict the model from generating vague or inaccurate expressions, ensure precise citation of key indicators like plasma concentrations, and handle statistical concepts like confidence intervals.
Configuration Settings
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
maxContext | 3000 tokens | Ensures the system can carry the background of bioequivalence studies, patient characteristics, and adverse event details across multiple turns, preventing loss of critical information. |
Recall Count | 10 items | Bioequivalence data is highly interconnected. Increasing the recall count helps cover more relevant research reports and adverse event cases, improving information completeness. |
Similarity Threshold | 0.75 | Balances accuracy and recall. Filters out highly relevant bioequivalence reports or adverse event records related to the query, reducing noise. |
Segment Length | 500 characters | Considering the detailed nature of clinical trial reports and adverse event descriptions, appropriately increasing the segment length ensures information coherence within a single paragraph. |
Rerank Return Count | 5 items | Based on the initial recall, reranking further optimizes the priority of core bioequivalence indicators (e.g., AUC, Cmax) and adverse events, improving answer quality. |
Common Mistakes
- The model fails to accurately cite specific plasma concentration-time curve data or statistical confidence intervals when answering bioequivalence-related questions. This occurs when prompts do not explicitly require the model to extract and present numerical values with units and ranges.
- When a user queries adverse event records for a specific drug batch, the system returns "No permission to operate this conversation record" or irrelevant citations. This happens due to improper knowledge base permission configuration or incorrect citation mechanism settings, causing the model to attempt to cite internal data the user cannot access or display unnecessary citation identifiers.
- In multi-turn conversations, the model cannot correctly associate specific subject groups or dosing regimens mentioned in previous turns with the current adverse event query. This occurs when
maxContextis set too low, leading to truncation of conversation history and loss of context for the model.
How to Confirm Proper Configuration
- Input bioequivalence questions containing specialized terminology and specific numerical values. Verify that the model's answer accurately presents key indicators like plasma concentration and Tmax, along with their units.
- Simulate a query about adverse events for a specific drug batch. Check if the answer includes specific adverse reaction descriptions related to that batch and confirm that no irrelevant citations or permission error messages are displayed.
- Conduct multi-turn conversation tests. In the second or third turn, reference subject characteristics or dosing information from previous turns. Observe if the model maintains contextual coherence and provides relevant answers.
- For a document containing an adverse event narrative, ask about the severity of an adverse event mentioned within it. Verify that the model can accurately extract and answer from the unstructured text.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.